Repotrectinib shows encouraging safety, efficacy for patients with ROS1+ NSCLC Presented ByDr Byoung Chul Cho, Yonsei Cancer Centre, South Korea TrialTRIDENT-1 ConferenceASCO 2019 TypePeer-reviewed article 15 July 2019 21:15